BioTuesdays
PhaseBio Pharmaceuticals

PhaseBio discontinues Phase 2 COVID-19 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) discontinued its Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of vasoactive intestinal peptide...

Cidara Therapeutics Logo

Cidara updates Phase 2 rezafungin data

Cidara Therapeutics (NASDAQ:CDTX) reported new data from its Phase 2 STRIVE trial evaluating once-weekly rezafungin for the treatment of candidemia and invasive candidiasis. The trial demonstrated that rezafungin...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.